Acetylcholinesterase(AChE) inhibitors are important research topics because of their wide range of associated health implications, especially for the treatment of Alzheimer's disease. The finding of novel AChE inhibitors is presented here. A docking screening model of AChE inhibitor was used to evaluate a series of 5H-thiazolo[3,2-a] pyrimidine derivatives. The virtual screening hits were analyzed in drug likeness and physical-chemical features, therefore were focused to those compounds in the present article. To investigate the relationship between the bioactivities and the structures, 10 target compounds with the 5H-thiazolo[3,2-a]pyrimidine scaffold were synthesized as potential AChE inhibitors, and the pharmacological assay result also conformed, some compounds displayed considerable inhibitory effects with inhibition rates above 50% at 10 µM, and all their core structures are very different from those of known AChE inhibitors. The results demonstrate the effectiveness and validity of the virtual screening approach especially of the docking screening approach, and provide a starting point for the development of novel drugs to treat Alzheimer's disease.
Introduction
Alzheimer's disease (AD) is a chronic, slowly progressive neurodegenerative disorder, clinically characterized by an impairment of cognitive function. 1 AD is commonly believed to be associated with the dysfunction of the central cholinergic system. Acetylcholinesterase (AChE) plays a key role in the regulation of the cholinergic system. 2 And hence, inhibition of AChE has emerged as one of the most promising strategies for the treatment of AD. [3] [4] [5] Molecular docking is an efficient tool for investigating receptor-ligand interactions and for virtual screening, which plays a key role in rational drug design, especially when the crystal structure of a receptor or enzyme is available. [6] [7] [8] Therefore, in this study we first explored the AChE complex structures with dozens of known AChE inhibitors which are available from the Protein Data Bank (PDB). The result was used as the docking protocol to investigate their global binding mode of AChE. In addition, a small focused library with 5H-thiazolo[3,2-a]pyrimidine derivatives was built and screened virtually using the docking method.
The docking model built with Autodock 4.0 software was generated and checked for its reliability, we went through a self-compiled 3D database to get some preferable candidates for future synthesis. On the basis of the obtained hits, we undertook an exploratory study of their in vitro AChE inhibitory effects.
The aim of this study was to demonstrate the strategy of utilizing computer-aided drug discovery in search for AChE inhibitors in the field of new scaffolds. We believe that this procedure will be helpful in the design of novel AChE inhibitory compounds.
Results and Discussion
Generation of the docking model for AChE inhibitors. Virtual screening Docking models have often been proven to be useful tools for rationalizing ligand-target interaction and for making this information available to virtual screening techniques. For this study the model was obtained starting from 3D structural information, of which those protein-ligand complexes are available as PDB files, using the AutoDock 4.0 software package.
Molecular modeling studies were performed using human AChE, since they represent the pharmacological target for the development of new drugs, also considering of Torpedo californica AChE complexes. Nevertheless, a comparison of their amino acid sequences revealed an overall identity of 59.09% (1B41 vs 1W6R). As to the binding site, which is to mean, the residues within 15nm of the ligand, the identity rose up to 75.6%(1B41 vs 1W6R), only small differences were found comparing the amino acid composition of the active sites, which could be seen clearly in Figure 1 . On the basis of extensive X-ray crystallography and mutagenesis studies, AChE appears to have a binding domain that interacts with divergent enzyme inhibitors, which includes those residues as D74, W86, N87, G120, G121, G122, Y124, S125, G126, L130, E202, S203, F297, Y337, F338, Y341, H447, G448, and I451, showed in Therefore, the docking procedure which indicates the enzyme-inhibitor binding interactions was used for the virtual screening experiment, using a protocol including molecular mechanics, genetic algorithm, and Lamarckian GA calculations. On the basis of the obtained hits, 5H-thiazolo[3,2-a]pyrimidine derivatives emerged as promising candidates. Selected conformers of compounds were docked into the human AChE structure (PDB code 1B41), showed in Figure 3 and Figure 4 .
As a validation of the docking procedure the structure of galantamine was docked back into the active site of the enzyme with all water molecules deleted. Eight out of the ten top scoring docking configurations resembled almost exactly as the crystallized complex of galanthamine-enzyme, the RMSD was below 1.0. This allowed to the conclusion that the results obtained with the applied docking procedure were meaningful. shown as stick models. The residues interacting with the ligand, are shown as line models.
(Hydrogens and water molecules are omitted for the sake of clarity, all colored in atom type).
Chemistry
Compound 1-10 were obtained in satisfactory yields(all above 80%), and the synthetic pathways to obtain the targets are described in Schemes 1. The synthesis of the dihydropyrimidines is a well known three component one pot reaction of a substituted aldehyde, 1,3-dicarbonyl compound and thiourea (Biginelli reaction).
9-10 The
Hantzsch-type condensation of dihydropyrimidines with a substituted phenacyl chlorides led to the 3-substituted 5H-thiazolo[3,2-a]pyrimidine derivatives. 11, 12 The Hantzsch-type condensation may yield several isomerisms. The yields could result either from initial formation of oxyalkyl, aminoalkyl or isomeric sulfane, then condensed via elimination of water. However, the product made out to be in the last mechanism. Analyzing the chemical shifts of the 5H-thiazolo[3,2-a]pyrimidine scaffold in 1 H-NMR spectra, we could find that they were all in the narrow range of 7.5-7.3 ppm, far from 5.5 ppm, which could be assigned as the proton of C2 in the 5H-thiazolo[3,2-a]pyrimidine scaffold. Therefore, the substitute should be at the C3 in the 5H-thiazolo[3,2-a]pyrimidine scaffold. Those assigned structures could be confirmed by NOE assay, HMBC, HSQC and COSY spectra. Taking compound 4 for example, showed in the Figure 5 below, in the 1D selective ROESY experiments with 500ms mixing time, when the proton at 6.22 ppm was irradiated, the protons at 7.32 ppm displayed the NOE effects; and vice versa. Thus, we could conclude that the substituting aryl groups of 5H-thiazolo[3,2-a]pyrimidine scaffold was spatially near to each other. The Hantzsch-type condensation in AcONa/AcOH buffer led to form 3-substituted 5H-thiazolo[3,2-a]pyrimidine derivatives confirmed in all respects (chemical shifts, NOE effects and so on). Table 1 illustrates the biological activity of compounds against freshly prepared human AChE, in comparison to the neostigmine bromide. Human AChE (SigmaC-1682) 0.5unit was used. Each performed in double. The incubation time was 20 min, with gentle shake.
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Conclusions
In summary, we disclosed a rational design of novel series of potent 3-substituted 5H-thiazolo[3,2-a]pyrimidine derivatives as AChE inhibitors, binding to the active site of human AChE substrate domain. Molecular modeling studies led to the identification of 3-substituted 5H-thiazolo[3,2-a]pyrimidine derivatives, and the biological data were in full agreement with the proposed binding mode, confirming our hypothesis. 3-Substituted 5H-thiazolo[3,2-a]pyrimidine derivatives may represent a leading structure to generate enzyme inhibitors as novel therapeutical entities for severe neurodegenerative diseases. The pharmacological study of 3-substituted 5H-thiazolo[3,2-a]pyrimidine derivatives targeting Alzheimer's disease will be reported in due course.
Experimental Section
General Procedures. All reagents and solvents were purchased from common commercial suppliers and were used without further purification. All melting points were taken in open capillary tubes and are uncorrected. The nuclear magnetic resonance spectra were recorded in DMSO-d 6 To identify the possible binding mode of the compounds with the AChE, docking simulations were performed by means of the AutoDock 4.0 package software(UCSF AutoDock4.0, USA) and using the cocrystal between the AChE and Fasciculin (PDB code 1B41). Fasciculin was removed off, and the missing atoms were properly completed by means of the SPDB Viewer(GSK SPDB Viewer, Version3.7, Swiss). Hydrogen atoms were added to the protein amino acids, and the atomic partial charges were loaded in UCSF Chimera software package.
General procedures of synthesis 3-substituted 5H-thiazolo[3,2-a]pyrimidine derivatives
In a typical procedure a mixture of 5.00 mmol of substituted aldehyde, 7.50 mmol of ethyl acetoacetate or acetoacetone, 6.50 mmol thiourea, 5 mL of EtOH, and two drops of concentrated HCl was stirred at 50-55 °C for 10 h. One drop of concentrated HCl was added every 2 h. After the mixture was allowed to stand at 0 °C overnight, the precipitate was filtered to give 6-methyl-3, 4-dihydropyrimidine-2(1H)-thione in good yields. Then used to react with substituted phenacyl chloride respectively. In a typical procedure a mixture of 6-methyl-3,4-dihydropyrimidine-2(1H) -thione (10 mmol), substituted phenacyl chloride (10 mmol) and AcONa/AcOH (2g/20mL) was refluxed for 8-24 h. After completion of the reaction as indicated by TLC, the reaction liquid was cooled to room temperature, which crystallized as 3-substituted 5H-thiazolo[3,2-a]pyrimidine derivatives. The precipitate, in each case, was collected, and recrystallized from ethanol to give the target compounds 1-10. 
